Todd Fromer | Managing Partner, KCSA Strategic Communications, IR |
Carl Schwartz | Chief Executive Officer |
Richard Gabriel | Head of External Business Development for TumorGenesis |
Bob Myers | Chief Financial Officer |
Gerry Vardzel | Chief Executive Officer, Helomics Corporation |
Dana Allen | Goldman Sachs |
Good day, everyone, and welcome to the Precision Therapeutics Q1 2018 Business Update Conference Call. Today’s call is being recorded. At this time I would like to turn the call over to Todd Fromer. Please go ahead.
Thank you all for participating in today's call to discuss Precision Therapeutics financial results for the first fiscal quarter of 2018.